Title | Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Okuya, M, Matsunaga, S, Ikuta, T, Kishi, T, Iwata, N |
Journal | J Alzheimers Dis |
Volume | 66 |
Issue | 4 |
Pagination | 1379-1387 |
Date Published | 2018 |
ISSN | 1875-8908 |
Abstract | A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n = 801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference = 2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD. |
DOI | 10.3233/JAD-180888 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 30452419 |